For our latest recommendation, we revisit one of the world's most prominent technology companies, Mi...
Vertex: Targeting Cystic Fibrosis
11/03/2016 10:00 am EST
This stock is a biotech company that develops breakthrough drugs and carries them through to the manufacturing process, informs Crista Huff, editor of Cabot Undervalued Stocks Advisor.
Vertex Pharmaceuticals (VRTX) is a clear leader in the treatment of cystic fibrosis (CF), a disabling and deadly genetic disease affecting the lungs.
Vertex has lengthy patent protection on the only two disease-modifying drugs within that rare-disease niche. Its projected one-, three- and five-year revenue growth rates are all significantly higher than those of its US biotech peer group.
Vertex reported that its research on a new "triplet" pill for cystic fibrosis is moving into Phase II studies. The treatment combines Vertex' currently marketed drug, ivacaftor (Kalydeco), with two additional drugs.
The market was highly-concerned that the Phase II studies might be delayed, so this announcement should signal the end of the recent downturn in the share price.
VRTX is a vastly undervalued, aggressive growth stock. The company is expected to report third-quarter EPS of 20 cents on the afternoon of October 25th.
VRTX had a big pullback after its summertime run-up. The pullback lasted longer than I expected, however, it's in tandem with a pullback among biotech stocks.
Vertex reported third-quarter 2016 earnings per share (EPS) of 16 cents vs. the consensus estimate of 18 cents. Revenues were $413.5 million vs. the consensus estimate of $419 million.
The stock bounced at $80, half a dozen times this year. I don't see any red flags. Buy VRTX now. There's upside resistance at $110, in the low $130s, and again at the August 2015 high of $141. Buy.
By Crista Huff, Editor of Cabot Undervalued Stocks Advisor
Related Articles on STOCKS
We hold three biotech stocks in our growth portfolio — Biogen (BIIB), Bioverativ (BIVV), and R...
Under the guise of clamping down on “widespread corruption,” Prince Mohammed bin Salman ...
Leading value investor and money manager John Buckingham sees upside potential in two banking stocks...